 |
JOURNAL TOOLS |
| Opzioni di pubblicazione |
| eTOC |
| Per abbonarsi |
| Sottometti un articolo |
| Segnala alla tua biblioteca |
ARTICLE TOOLS |
| Publication history |
| Estratti |
| Permessi |
| Per citare questo articolo |
| Share |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW Free access
Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):872-6
DOI: 10.23736/S0392-0488.18.06143-6
Copyright © 2018 EDIZIONI MINERVA MEDICA
lingua: Inglese
Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?
Gian Luigi GIOVENE 1 ✉, Luca GIACOMELLI 2, AIDA (Italian Association of Outpatient Dermatologists) Working Group 
1 Private Practitioner, Perugia, Italy; 2 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
The fixed-combination of Cal/BD aerosol foam is now entering the Italian market. This drug was developed with a technology that allows an enhanced penetration of the active ingredients into the skin. This enhanced penetration improves local bioavailability and, consequently, Cal/BD aerosol foam therapy is associated with improved clinical outcomes if compared with other products with the same components. The efficacy and safety of Cal/BD aerosol foam were confirmed both in clinical trials and in “field-practice” studies. This short review discusses current evidence on the Cal/BD aerosol foam combination; some preliminary data collected in the Italian clinical practice will be also presented.
KEY WORDS: Calcipotriene - Betamethasone dipropionate - Aerosol foam